EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Medicines Shortages
Across Europe, and in other parts of the world, the difficulties experienced with the availability of medicines are becoming an increasing problem for pharmacists in practise. Indeed, a survey conducted by EAHP in 2012 suggested that nearly 80% of hospital pharmacists in Europe are experiencing medicines shortages in their hospital on a weekly or daily basis. The subsequent negative impacts for patients are multi-faceted, including not only potential interruption of supply of their medication, but also the distraction of resource from the pharmacy from other patient-centred activities when managing a supply disruption, and the added stress and work pressures for hospital pharmacies that can contribute to heightened risk of medication errors occurring.
Clearly the situation cannot be allowed to become worse and action must be taken. EAHP, in collaboration with partners, is making representations at the European level for new measures to be taken by the industry, by the European Commission and the European Medicines Agency. Can 2013 be the year that partners in the medicines supply chain achieved a turnaround in the disturbing shortages trend?
Pricing of medicines in an era of public spending austerity
No country in Europe is immune from the effects that the new era of public spending austerity is having on the delivery of public services of all kinds. Spending in health services is coming under renewed scrutiny and one target for reduced expenditure is the medicines bill. With much development in the past ten years in areas such as generic substitution and health technology assessment, new innovative approaches to pricing are in development in many countries, including various forms of risk sharing such as cost-sharing incentives for the introduction of new medicines, and pricing based on the value/outcome delivered by a medicine. Such novel approaches offer many opportunities, and could see the growth of the hospital pharmacist’s role in providing evidence of the outcomes of medicine use. However, are there also threats to transparency, and can a fair form of measuring outcome ever be developed?
The regulation of medical devices
The regulation of medical devices has been placed in the media spotlight as a result of the PIP breast implant scandal, with some politicians going as far as to suggest devices should be subject to the same regulatory regime as medicines. Whilst recent proposals from the European Commission have not gone this far, there is a clear recognition that the regulatory environment needs improvement, especially in ensuring that there is a common high standard for assessment of devices across Europe. But will the proposals really tackle all the issues, and do they take due account of the role of the hospital pharmacist in procuring, advising and monitoring the use of devices in hospitals?
The reform of clinical trial regulation in Europe
There is universal acceptance that the 2005 European Directive on the regulation of clinical trial assessment procedures in Europe did not achieve its objectives of simplifying and improving the environment for the conduct of trials. Accordingly, proposals from the European Commission in 2012 to create a new Regulation, with more centralized and harmonized processes for trial submission, including greater distinctions to be made in relation to requirements for high and low risk trials, have been met with broad acceptance.
Where there is debate and contention however is in relation to just how transparent the information derived in the trial process should be. EAHP, alongside other organisations, is pushing for greater levels of transparency to aid participating hospital pharmacies in their involvement in the trial process, and to maximize the confidence all stakeholders have in the European system of trial regulation. The Press Conference at the 18th Congress of the EAHP gives space to discuss EAHP’s proposed improvements to clinical trial regulation in more detail and set out the range of benefits that can be achieved by increasing trial result transparency.
2014 European Summit on the future of Hospital Pharmacy
Vision is being able to see where one is going, and to see what’s ahead, in both literal and figurative senses. Vision is about knowing your destination, so that you know if you’re there, and even more importantly knowing if you’re off course and not any closer to your goal. 5 years after the FIP Basel statements, which set out international hospital pharmacy competencies, and in the context of ongoing Pharmine activity into the nature of European hospital pharmacy, it is an appropriate time to stop and ask important questions such as:
• Where do we want hospital pharmacy in Europe to be in 10, 20 & 30 years’ time?
• How do we get there?
• When we review the last 50 years of hospital pharmacy development, what can we learn about the future?
• How can we keep ahead of change, and shape the future, rather than be shaped by the future?
• What challenges will be faced in achieving the vision for European hospital pharmacy?
EAHP plans to host a significant event in 2014 to set the pathways for the development of European Hospital Pharmacy in a manner that inspires the confidence and support of not only hospital pharmacists, but patients and our fellow health professionals. The Press Conference at the 18th Congress of the EAHP provides an opportunity to set out in more detail the plans for this event and how its outcomes will intend to raise practise in every European country.
